ClinicalTrials.gg
CompletedNCT01205321Updated Jan 21, 2013

PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers

A Phase 1 interventional study of Bombesin (68Ga) labeled (BAY86-7548) and Bombesin (68Ga) labeled (BAY86-7548) in Diagnostic Imaging, sponsored by Life Molecular Imaging SA. Completed at 3 sites in 3 countries. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2013-01-21.

Sponsored by Life Molecular Imaging SA (part of Lantheus Holdings, Inc.) · Phase 1, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
45 Years and older
Sex
Male
01

Study summary

Visual assessment of diagnostic PET/CT (positron emission tomography/computed tomography) images obtained after a single intravenous injection of BAY86-7548 in patients with cancer.

02

Conditions studied

  • Diagnostic Imaging

Browse trials for

Keywords

  • Neoplasm
  • PET/CT diagnosis
  • PET tracer
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 19 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Life Molecular Imaging SA is the lead sponsor of 8 studies on the registry; none are open to participants now.

First submitted before Life Molecular Imaging SA became part of Lantheus Holdings, Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteers:

    • males, >/=50 and \</= 65 years of age
  • Cancer patients:

    • males >/= 45 years of age
    • Patients had an MRI of the prostate and/or a positive choline or acetate PET/CT for diagnosis (Note: MRI, choline and acetate PET/CT are optional for primary prostate cancer patients) of recurrence prostate cancer and the primary cancer disease is/ will be confirmed.
    • The prostate cancer is histologically confirmed and results of histology are available.
    • Patients with primary prostate cancer: >/= 20 percent of material should be affected by cancer in the histopathological evaluation.
    • Patients with primary prostate cancer: Patient is scheduled to undergo prostatectomy.

Exclusion criteria

Exclusion Criteria:

  • Concurrent severe and/or uncontrolled and/or unstable other medical disease (e.g. poorly controlled diabetes, congestive heart failure, myocardial infarction within 12 months prior to planned injection of BAY86-7548, unstable and uncontrolled hypertension, chronic renal or hepatic disease, severe pulmonary disease) which could compromise participation in the study
  • Known sensitivity to the study drug or components of the preparation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Bombesin (68Ga) labeled (BAY86-7548)

  • Experimental
    Arm 2

    Drug: Bombesin (68Ga) labeled (BAY86-7548)

Interventions

  • Cancer patients, single intravenous bolus injection of 140 MBq BAY86-7548 on day one of the treatment period, PET/CT

  • Healthy volunteers, single intravenous bolus injection of 140 MBq BAY86-7548 on day one of the treatment period, whole body PET/CT for determination of effective dose, kinetics of BAY86-7548 in blood

06

What researchers measure

Primary outcomes

  1. Visual assessment of lesions

    Time frame: Day of study drug administration

Secondary outcomes

  1. Quantitative analysis of BAY86-7548 uptake into lesions (Standardized Uptake Values = SUVs)

    Time frame: Day of study drug administration

  2. ECG (significant abnormalities)

    Time frame: At least 3 times until one day after treatment

  3. Blood pressure

    Time frame: At least 3 times until one day after treatment

  4. Serum protein

    Time frame: At least 3 times until one day after treatment

  5. Serum creatinine

    Time frame: At least 3 times until one day after treatment

  6. Serum GOT (Glutamat-Oxalacetat-Transaminase)

    Time frame: At least 3 times until one day after treatment

  7. Adverse events collection

    Time frame: Continuously for at least 5 days after treatment

07

Study locations

3 sites
  • Turku, FIN-20521, Finland
  • Ulm, Baden-Württemberg 89081, Germany
  • Zürich, 8091, Switzerland
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Nov 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2010
First posted
Sep 20, 2010
Start
Nov 2010
Primary completionActual
Nov 2011
CompletionActual
Dec 2011
Last update
Jan 21, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01205321
Responsible party
Sponsor
First posted
Sep 20, 2010
Start date
Nov 2010
Primary completion
Nov 2011
Completion
Dec 2011
Last update
Jan 21, 2013

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gallium-68

Start the discussion